Stock Events

Stock Events

PMV Pharmaceuticals 

$1.2900
13
+$0.05+4.03% 20:00 Today
-$0.05-3.88%20:16After hours

Statistics

Day High
1.35
Day Low
1.24
52W High
1.88
52W Low
1.02
Volume
529,981
Avg. Volume
422,671
Mkt Cap
68.96M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.45
-0.41
-0.38
-0.34
Expected EPS
-0.373333
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-77.74MNet Income

Analyst Ratings

4.33Average Price Target
The highest estimate is 5.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PMVP. It's not an investment recommendation.
Quince Therapeutics
4
QNCX
NVIDIA
3
NVDA
Ford Motor
3
F
Unitedhealth Group
3
UNH

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is involved in gene editing, a technology that could directly compete with PMV Pharmaceuticals' precision oncology approaches.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is another key player in the CRISPR/Cas9 gene editing space, potentially offering alternative treatments to those developed by PMV Pharmaceuticals.
Editas Medicine
EDIT
Mkt Cap485.31M
Editas Medicine operates in the genome editing field, specifically using CRISPR technology, which could rival PMV Pharmaceuticals' cancer therapies.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics focuses on base editing, a form of gene editing that could compete with PMV Pharmaceuticals' approach to targeting cancer at the genetic level.
Allogene Therapeutics
ALLO
Mkt Cap697.89M
Allogene Therapeutics specializes in allogeneic CAR T-cell therapies, which could be an alternative to PMV Pharmaceuticals' targeted cancer treatments.
Fate Therapeutics
FATE
Mkt Cap291.16M
Fate Therapeutics is developing programmed cellular immunotherapies, which could compete with PMV Pharmaceuticals' approach to cancer treatment.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR T-cell therapy, competing in the oncology space with PMV Pharmaceuticals.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies but is expanding into gene therapy, potentially competing in the broader biotech space with PMV Pharmaceuticals.

About

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.
Show more...
CEO
David H. Mack
Employees
54
Country
United States
ISIN
US69353Y1038

Listings

XNAS
US
PMVP
BOATS
BOATS
PMVP.BOATS

0 Comments

Share your thoughts

FAQ

What is PMV Pharmaceuticals stock price today?▼
The current price of PMVP is $1.29 USD — it has increased by +4.03% in the past 24 hours. Watch PMV Pharmaceuticals stock price performance more closely on the chart.
What is PMV Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange PMV Pharmaceuticals stocks are traded under the ticker PMVP.
Is PMV Pharmaceuticals stock price growing?▼
PMVP stock has risen by +5.74% compared to the previous week, the month change is a +10.26% rise, over the last year PMV Pharmaceuticals has showed a -10.42% decrease.
What is PMV Pharmaceuticals market cap?▼
Today PMV Pharmaceuticals has the market capitalization of 68.96M
When is the next PMV Pharmaceuticals earnings date?▼
PMV Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were PMV Pharmaceuticals earnings last quarter?▼
PMVP earnings for the last quarter are -0.34 USD per share, whereas the estimation was -0.39 USD resulting in a +12.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is PMV Pharmaceuticals revenue for the last year?▼
PMV Pharmaceuticals revenue for the last year amounts to 0 USD.
What is PMV Pharmaceuticals net income for the last year?▼
PMVP net income for the last year is -77.74M USD.
How many employees does PMV Pharmaceuticals have?▼
As of September 04, 2026, the company has 54 employees.
In which sector is PMV Pharmaceuticals located?▼
PMV Pharmaceuticals operates in the Health & Wellness sector.
When did PMV Pharmaceuticals complete a stock split?▼
PMV Pharmaceuticals has not had any recent stock splits.
Where is PMV Pharmaceuticals headquartered?▼
PMV Pharmaceuticals is headquartered in PRINCETON, United States.